Inactivation of the Mouse Huntington's Disease Gene Homolog Hdh
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is a dominant neurodegenerative disorder caused by expansion of a CAG repeat in the gene encoding huntingtin, a protein of unknown function. To distinguish between "loss of function" and "gain of function" models of HD, the murine HD homolog Hdh was inactivated by gene targeting. Mice heterozygous for Hdh inactivation were phenotypically normal, whereas homozygosity resulted in embryonic death. Homozygotes displayed abnormal gastrulation at embryonic day 7.5 and were resorbing by day 8.5. Thus, huntingtin is critical early in embryonic development, before the emergence of the nervous system. That Hdh inactivation does not mimic adult HD neuropathology suggests that the human disease involves a gain of function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to α-syn in PD and Tau in AD, polyQ-HTT aggregates exert toxic gain-of-function effects, forming β-sheet-rich structures that disrupt essential cellular pathways and cause neurotoxicity [169,170].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [169]
In the citing paper
“Similar to α-syn in PD and Tau in AD, polyQ-HTT aggregates exert toxic gain-of-function effects, forming β-sheet-rich structures that disrupt essential cellular pathways and cause neurotoxicity [169,170].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [169]
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Self-citationVerkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.
Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., & Roder, J. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8424 · Cited by 2,329
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Self-citationAbsence of expression of the FMR-1 gene in fragile X syndrome
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476
Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
Tybulewicz, V. L. J., Crawford, C. E., Jackson, P. K., Bronson, R. T., & Mulligan, R. C. (1991) · Cell · doi:10.1016/0092-8674(91)90011-m · Cited by 1,281
Fmr1 knockout mice: A model to study fragile X mental retardation
THEDUTCHBELGIANFRAGILEXCONSOR (1994) · Cell · doi:10.1016/0092-8674(94)90569-x · Cited by 1,035
Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, V. M., Richman, J. M., Zeisler, J., Borowski, A., Marth, J. D., Phillips, A. G., & Hayden, M. R. (1995) · Cell · doi:10.1016/0092-8674(95)90542-1 · Cited by 872
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Self-citationDNA methylation represses FMR-1 transcription in fragile X syndrome
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680
Research works printed but not linked: 3
- CELL 78: 23 (1994).
- Nagy, A., Gene Targeting: A Practical Approach: 147 (1993).
- Wurst, W., Gene Targeting: A Practical Approach: 31 (1993).
Cited by
Items 401–500 of 885
Walsh, R., Storey, E., Stefani, D., Kelly, L. C., & Turnbull, V. J. (2005) · Neurotoxicity Research · doi:10.1007/bf03033775 · Cited by 32
Developing intrabodies for the therapeutic suppression of neurodegenerative pathology
Messer, A. C., Lynch, S. M., & Butler, D. C. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903176387 · Cited by 32
Irmak, D., Fatima, A., Gutiérrez-García, R., Rinschen, M. M., Wagle, P., Altmüller, J., Arrigoni, L., Hummel, B., Klein, C., Frese, C. K., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy304 · Cited by 32
Origins and evolution of huntington disease chromosomes
Andrew, S. E., & Hayden, M. R. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90013-6 · Cited by 32
Animal Models of Neurological Disease
Shah, A., Garzón-Muvdi, T., Mahajan, R. K., Duenas, V. J., & Quiñones-Hinojosa, A. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-5819-8_3 · Cited by 32
Benn, J., Mukadam, A. S., & McEwan, W. A. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.09.012 · Cited by 31
Dietz, K. N., Stefano, L. D., Maher, R. C., Zhu, H., MacDonald, M. E., Gusella, J. F., & Walker, J. A. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu446 · Cited by 31
Self-citationThe Role of Apoptosis in Neurodegenerative Diseases
Desjardins, P., & Ledoux, S. (1998) · Metabolic Brain Disease · doi:10.1023/a:1020605112755 · Cited by 31
Kim, S. H., Thomas, C. A., André, V. M., Cummings, D. M., Cepeda, C., Michael, S. L., & Ehrlich, M. E. (2011) · ASN NEURO · doi:10.1042/an20110009 · Cited by 31
Expanded glutamines and neurodegeneration – a gain of insight
Bates, G. P. (1996) · BioEssays · doi:10.1002/bies.950180303 · Cited by 31
Kandasamy, M., & Aigner, L. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00037 · Cited by 30
Functions of Huntingtin in Germ Layer Specification and Organogenesis
Nguyen, G. D., Molero, A. E., Gökhan, Ş., & Mehler, M. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072698 · Cited by 30
Discovery of a Novel Small-Molecule Targeting Selective Clearance of Mutant Huntingtin Fragments
Coufal, M., Maxwell, M. M., Russel, D. E., Amore, A. M., Altmann, S. M., Hollingsworth, Z. R., Young, A. B., Housman, D. E., & Kazantsev, A. G. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107299428 · Cited by 30
Mouse Models of Human CAG Repeat Disorders
Burright, E. N., Orr, H. T., & Clark, H. B. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb00896.x · Cited by 30
Replacement of huntingtin exon 1 by trans-splicing
Rindt, H., Yen, P., Thebeau, C. N., Peterson, T. S., Weisman, G. A., & Lorson, C. L. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1083-5 · Cited by 29
Rac1 Activity Is Modulated by Huntingtin and Dysregulated in Models of Huntington’s Disease
Tousley, A. R., Iuliano, M., Weisman, E., Sapp, E., Zhang, N., Vodička, P., Alexander, J. S., Aviolat, H., Gatune, L. W., Reeves, P., et al. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-180311 · Cited by 29
GENETICALLY MODIFIED MICE IN NEUROPHARMACOLOGY
Brusa, R. (1999) · Pharmacological Research · doi:10.1006/phrs.1998.0457 · Cited by 29
Kumar, U., Asotra, K., Patel, S. C., & Patel, Y. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6473 · Cited by 29
How Does the Huntington's Disease Mutation Damage Cells?
Rubinsztein, D. C. (2003) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2003.37.pe26 · Cited by 29
Choi, Y., Kadakkuzha, B. M., Liu, X.-A., Akhmedov, K., Kandel, E. R., & Puthanveettil, S. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103004 · Cited by 28
Dragatsis, I., Dietrich, P., Ren, H., Deng, Y. P., Mar, N. D., Wang, H. B., Johnson, I. M., Jones, K. R., & Reiner, A. J. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.12.015 · Cited by 28
Tomczyk, M., Glaser, T., Slominska, E. M., Ulrich, H., & Smolenski, R. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126545 · Cited by 28
RNAi Therapy for Neurodegenerative Diseases
Boudreau, R. L., & Davidson, B. L. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)75003-7 · Cited by 28
Isolation and characterization of the rat huntingtin promoter
Holzmann, C., Mäueler, W., Petersohn, D., Schmidt, T., Thiel, G., Epplen, J. T., & Rieß, O. (1998) · Biochemical Journal · doi:10.1042/bj3360227 · Cited by 27
Correction: Functions of Huntingtin in Germ Layer Specification and Organogenesis
Nguyen, G. D., Molero, A. E., Gökhan, Ş., & Mehler, M. F. (2013) · PLoS ONE · doi:10.1371/annotation/edee8dfa-6b2a-44f4-866a-098f186e27f0 · Cited by 27
RNA-Targeting CRISPR/CasRx system relieves disease symptoms in Huntington’s disease models
Lin, Y., Li, C., Chen, Y., Gao, J., Li, J., Huang, C., Liu, Z., Wang, W., Zheng, X., Song, X., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00794-w · Cited by 26
Trinucleotide Repeat Expansion Diseases, RNAi, and Cancer
Murmann, A. E., Yu, J., Opal, P., & Peter, M. E. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.08.004 · Cited by 26
Drugging unconventional targets: insights from Huntington's disease
Yu, S., Liang, Y., Palacino, J. J., DiFiglia, M., & Lu, B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.12.001 · Cited by 25
SMAD transcription factors are altered in cell models of HD and regulate HTT expression
Bowles, K. R., Stone, T., Holmans, P., Allen, N., Dunnett, S. B., & Jones, L. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.12.005 · Cited by 25
Sirtuins as Modifiers of Huntington's Disease (HD) Pathology
Neo, S. H., & Tang, B. L. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.013 · Cited by 25
Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases
Zain, R., & Rjh, S. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00712-9 · Cited by 25
Huntingtin is associated with cytomatrix proteins at the presynaptic terminal
Yao, J., Ong, S., & Bajjalieh, S. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.10.003 · Cited by 25
Dictyostelium discoideum as a Model for Investigating Neurodegenerative Diseases
Haver, H. N., & Scaglione, K. M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.759532 · Cited by 24
Murmann, A. E., Patel, M., Jeong, S., Bartom, E. T., Morton, A. J., & Peter, M. E. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05494-1 · Cited by 24
CAG repeat expansion in the Huntington’s disease gene shapes linear and circular RNAs biogenesis
Ayyildiz, D., Monziani, A., Tripathi, T., Döring, J., Bergonzoni, G., Kerschbamer, E., Leva, F. D., Pennati, E., Donini, L., Kovalenko, M. V., et al. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010988 · Cited by 24
Galgoczi, S., Ruzo, A., Markopoulos, C., Yoney, A., Phan-Everson, T., Li, S., Haremaki, T., Metzger, J. J., Etoc, F., & Brivanlou, A. H. (2021) · Development · doi:10.1242/dev.199513 · Cited by 24
Genetic ablation and chemical inhibition of IP3R1 reduce mutant huntingtin aggregation
Bauer, P. O., Hudec, R., Ozaki, S., Okuno, M., Ebisui, E., Mikoshiba, K., & Nukina, N. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.10.096 · Cited by 24
Requirement for the Murine Zinc Finger Protein ZFR in Perigastrulation Growth and Survival
Meagher, M. J., & Braun, R. E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.8.2880-2890.2001 · Cited by 24
Molecular biology of Huntington's disease
McFarland, K. N., & Cha, J.-H. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00003-3 · Cited by 23
Premanifest and Early Huntington’s Disease
Wild, E. J., & Tabrizi, S. J. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199929146.003.0005 · Cited by 23
Genetic analysis of the GRIK2modifier effect in Huntington's disease
Zeng, W., Gillis, T., Hakky, M. M., Djoussé, L., Myers, R. H., MacDonald, M. E., & Gusella, J. F. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-62 · Cited by 22
Self-citationWild-type huntingtin regulates human macrophage function
O’Regan, G. C., Farag, S. H., Ostroff, G. R., Tabrizi, S. J., & André, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74042-8 · Cited by 22
Xu, S., Li, G., Ye, X., Chen, D., Chen, Z., Xu, Z., Daniele, M., Tambone, S., Ceccacci, A., Tomei, L., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010302 · Cited by 22
Lorincz, M. T., Detloff, P. J., Albin, R. L., & O'Shea, K. S. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.01.016 · Cited by 22
The molecular pathogenesis of repeat expansion diseases
Fujino, Y., & Nagai, Y. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200143 · Cited by 21
Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing
Cambon, K., Zimmer, V., Martineau, S., Gaillard, M., Jarrige, M., Bugi, A., Miniarikova, J., Rey, M. J., Hässig, R., Dufour, N., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.05.001 · Cited by 21
Smalley, J. L., Breda, C., Mason, R. P., Kooner, G. S., Luthi‐Carter, R., Gant, T. W., & Giorgini, F. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1344-5 · Cited by 21
Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder
Haque, N. S. K., Borghesani, P. R., & Isacson, O. (1997) · Molecular Medicine Today · doi:10.1016/s1357-4310(97)01012-5 · Cited by 21
Huntingtin Interacting Proteins and Pathological Implications
Liu, L., Tong, H., Zhou, G., Liu, L., Chen, X.-X., Li, X.-J., Sun, Y., & Yang, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713060 · Cited by 20
CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases
Rahman, S., Datta, M., Kim, J., & Jan, A. T. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.014 · Cited by 20
Bonelli, R. M., & Beal, M. F. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00030-9 · Cited by 20
Candiani, S., Pestarino, M., Cattaneo, E. F., & Tartari, M. (2007) · BMC Developmental Biology · doi:10.1186/1471-213x-7-127 · Cited by 20
Chemical architecture of the basal ganglia
Graybiel, A. M., & Penney, J. B. (1999) · Handbook of chemical neuroanatomy · doi:10.1016/s0924-8196(99)80025-6 · Cited by 20
Huntington’s disease: A decade beyond gene discovery
Hogarth, P. (2003) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-003-0003-3 · Cited by 20
Myotonic dystrophy, knockouts, warts
Hamshere, M., & Brook, J. D. (1996) · Trends in Genetics · doi:10.1016/s0168-9525(96)80002-3 · Cited by 20
AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins
Evers, M. M., & Konstantinova, P. S. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1792880 · Cited by 20
HD and SCA1: Tales from two 30-year journeys since gene discovery
Thompson, L. M., & Orr, H. T. (2023) · Neuron · doi:10.1016/j.neuron.2023.09.036 · Cited by 19
Perspectives of autophagy-tethering compounds (ATTECs) in drug discovery
Ding, Y., Xing, D., Fei, Y., Luo, S., & Lu, B. (2024) · Medicine Plus · doi:10.1016/j.medp.2023.100004 · Cited by 19
New Approaches to the Pathology and Genetics of Neurodegeneration
Feany, M. Β. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091077 · Cited by 19
Molecular Biology of Huntington's Disease (HD) and HD-Like Disorders
Rubinsztein, D. C. (2003) · Elsevier eBooks · doi:10.1016/b978-012566652-7/50035-6 · Cited by 19
Mouse models as a tool for understanding neurodegenerative diseases
Ahmad‐Annuar, A., Tabrizi, S. J., & Fisher, E. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084221.82329.29 · Cited by 19
Global huntingtin knockout in adult mice leads to fatal neurodegeneration that spares the pancreas
Bragg, R. M., Mathews, E. W., Grindeland, A., Cantle, J. P., Howland, D., Vogt, T., & Carroll, J. B. (2024) · Life Science Alliance · doi:10.26508/lsa.202402571 · Cited by 18
Mathews, E. W., Coffey, S. R., Gärtner, A., Belgrad, J., Bragg, R. M., O’Reilly, D., Cantle, J. P., McHugh, C. A., Summers, A., Fentz, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64936-4 · Cited by 18
Liu, X., Wang, C.-E., Hong, Y., Zhao, T., Wang, G., Gaertig, M. A., Sun, M., Li, S., & Li, X. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006083 · Cited by 18
PIN1 Modulates Huntingtin Levels and Aggregate Accumulation: An In vitro Model
Carnemolla, A., Michelazzi, S., & Agostoni, E. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00121 · Cited by 18
Optimization of trans-Splicing for Huntington's Disease RNA Therapy
Rindt, H., Tom, C. M., Lorson, C. L., & Mattis, V. B. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00544 · Cited by 18
The evolution of the huntingtin-associated protein 40 (HAP40) in conjunction with huntingtin
Seefelder, M., Alva, V., Huang, B., Engler, T., Baumeister, W. P., Guo, Q., Fernández‐Busnadiego, R., Lupas, A. N., & Kochanek, S. (2020) · BMC Evolutionary Biology · doi:10.1186/s12862-020-01705-5 · Cited by 18
Use of Genetically Altered Stem Cells for the Treatment of Huntington’s Disease
Crane, A. T., Rossignol, J., & Dunbar, G. L. (2014) · Brain Sciences · doi:10.3390/brainsci4010202 · Cited by 18
Huntington’s Disease: Pathogenic Mechanisms and Therapeutic Targets
Wright, D. J., Renoir, T., Gray, L. J., & Hannan, A. J. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_4 · Cited by 18
Therapeutic Potential of Small Interfering RNA for Central Nervous System Diseases
Lovett‐Racke, A. E., Cravens, P. D., Gocke, A. R., Racke, M. K., & Stüve, O. (2005) · Archives of Neurology · doi:10.1001/archneur.62.12.1810 · Cited by 18
Gomez, G. T., Hu, H., McCaw, E. A., & Denovan‐Wright, E. M. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.12.004 · Cited by 17
Hypomorphic mutation of the mouse Huntington’s disease gene orthologue
Murthy, V., Tebaldi, T., Yoshida, T., Erdin, S., Calzonetti, T., Vijayvargia, R., Tripathi, T., Kerschbamer, E., Seong, I. S., Quattrone, A., et al. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1007765 · Cited by 17
Self-citationObsessive-Compulsive Disorder Symptoms in Huntington's Disease: A Case Report.
Molano-Eslava, J. C., Iragorri-Cucalón, Á., Ucrós-Rodríguez, G., Bonilla-Jácome, C., Tovar-Perdomo, S., Herin, D. V., & Orozco-Cabal, L. F. (2008) · Revista Colombiana de Psiquiatría · doi:10.1901/jaba.2008.37-644 · Cited by 17
Neurobiology of Huntington’s Disease
Souza, R. A. G. D., & Leavitt, B. R. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_353 · Cited by 17
Visualization of the Dynamics of Gene Expression in the Living Mouse
Ryan, A. B., & Scrable, H. J. (2004) · Molecular Imaging · doi:10.1162/15353500200403193 · Cited by 17
Self-citationPin1-Catalyzed Conformation Changes Regulate Protein Ubiquitination and Degradation
Jeong, J., Usman, M., Li, Y., Zhou, X. Z., & Lu, K. P. (2024) · Cells · doi:10.3390/cells13090731 · Cited by 16
Structure of the Huntingtin F-actin complex reveals its role in cytoskeleton organization
Carpentier, R., Kim, J., Capizzi, M., Kim, H., Fäßler, F., Hansen, J. M., Kim, M. J., Denarier, É., Blot, B., Degennaro, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw4124 · Cited by 16
SRCP1 Conveys Resistance to Polyglutamine Aggregation
Santarriaga, S., Haver, H. N., Kanack, A. J., Fikejs, A. S., Sison, S. L., Egner, J. M., Bostrom, J. R., Seminary, E. R., Hill, R. B., Link, B. A., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.008 · Cited by 16
Nuclear Receptor Coactivator PNRC2 Regulates Energy Expenditure and Adiposity
Zhou, D., Shen, R., Ye, J. J., Li, Y., Tsark, W. M. K., Isbell, D., Tso, P., & Chen, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703234200 · Cited by 16
Toxic effects of expanded ataxin-1 involve mechanical instability of the nuclear membrane
Mapelli, L., Canale, C., Pesci, D., Averaimo, S., Guizzardi, F., Fortunati, V., Falasca, L., Piacentini, M., Gliozzi, A., Relini, A., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.01.016 · Cited by 16
Free-Energy Landscape of the Amino-Terminal Fragment of Huntingtin in Aqueous Solution
Binette, V., Côté, S., & Mousseau, N. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.01.015 · Cited by 16
Advances in Huntington’s disease: implications for experimental therapeutics
Feigin, A. (1998) · Current Opinion in Neurology · doi:10.1097/00019052-199808000-00012 · Cited by 16
Could metformin be therapeutically useful in Huntington’s disease?
Tang, B. L. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0072 · Cited by 15
Bensalel, J., Xu, H., Lu, M. L., Capobianco, E., & Wei, J. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-01022-w · Cited by 15
Casaca-Carreira, J., Toonen, L. J. A., Evers, M. M., Jahanshahi, A., van Roon‐Mom, W., & Temel, Y. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.007 · Cited by 15
Generation of mouse mutants as a tool for functional genomics
Nolan, P. M. (2000) · Pharmacogenomics · doi:10.1517/14622416.1.3.243 · Cited by 15
HTT loss-of-function contributes to RNA deregulation in developing Huntington’s disease neurons
Kozłowska, E., Ciołak, A., Adamek, G., Szcześniak, J., & Fiszer, A. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01443-5 · Cited by 14
Kim, H., Lenoir, S., Helfricht, A., Jung, T., Karneva, Z. K., Lee, Y., Beumer, W., van der Horst, G., Anthonijsz, H. J. A., Buil, L. C. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.154108 · Cited by 14
Huntingtin regulates calcium fluxes in skeletal muscle
Chivet, M., Cluskey, M. M., Nicot, A.-S., Brocard, J., Beaufils, M., Giovannini, D., Giannesini, B., Poreau, B., Brocard, J., Humbert, S., et al. (2022) · The Journal of General Physiology · doi:10.1085/jgp.202213103 · Cited by 14
Shing, K., Sapp, E., Boudi, A., Liu, S., Seeley, C., Marchionini, D. M., DiFiglia, M., & Kegel-Gleason, K. B. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106313 · Cited by 14
Sanders, S. S., Hou, J., Sutton, L. M., Garside, V. C., Mui, K. K. N., Singaraja, R. R., Hayden, M. R., & Hoodless, P. A. (2014) · Developmental Biology · doi:10.1016/j.ydbio.2014.11.018 · Cited by 14
Yang, W., Xie, J., Qiang, Q., Li, L., Lin, X., Ren, Y., Ren, W.-L., Liu, Q., Zhou, G., Wei, W., et al. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00421-5 · Cited by 14
Molecular Genetics of Huntington’s Disease
MacDonald, M. E. (1998) · Results and problems in cell differentiation · doi:10.1007/978-3-540-69680-3_2 · Cited by 14
Self-citationClinical significance of frontal cortex abnormalities in Huntington's disease
Wolf, R. C., & Klöppel, S. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.03.022 · Cited by 13
Tippett, L. J., Waldvogel, H. J., Snell, R. G., Vonsattel, J., Young, A. B., & Faull, R. L. M. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_5 · Cited by 13
Self-citationChen, X., Sun, Y., Chen, L., Chen, X.-S., Pan, M., Zhang, Y., Wang, Q., Yang, W., Yin, P., He, D., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04577-8 · Cited by 13
Advances in the genetics of movement disorders: implications for molecular diagnosis
Gasser, T. (1997) · Journal of Neurology · doi:10.1007/s004150050100 · Cited by 13
Huntington's disease: The mystery unfolds?
Petersén, Å., & Brundin, P. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53012-9 · Cited by 13
Huntingtin: new marker along the road to death?
Rosen, A. (1996) · Nature Genetics · doi:10.1038/ng0896-380 · Cited by 13
Genetic Aberrancies and Neurodegenerative Disorders
Mattson, M. (1999) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(08)x6002-x · Cited by 13
Metadata
- Authors
- Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J.-P., Gusella, J. F., Joyner, A. L., & MacDonald, M. E.
- Affiliations
- Massachusetts General Hospital (US)
- Mount Sinai Hospital (CA)
- Corresponding author
- MacDonald, Marcy E.
- Venue
- Science
- Published
- 1995-07-21
- Volume
- 269
- Issue
- 5222
- Pages
- 407-410
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2002644780
- Cited by
- 723
- References
- 29
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 15 · 2023: 16 · 2022: 18 · 2021: 26 · 2020: 20 · 2019: 22 · 2018: 20 · 2017: 26 · 2016: 20 · 2015: 21 · 2014: 33 · 2013: 22 · 2012: 32
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (NS 16367, NS32765, R01NS032765)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- Huntington's disease, huntingtin, gene targeting, embryonic lethality, gastrulation, loss of function, gain-of-function, CAG repeat expansion, mouse model, neurodegeneration
- MeSH terms
- Huntingtin Protein, Animals, Base Sequence, Cell Line, Ectoderm, Female, Embryonic and Fetal Development, Genotype, Heterozygote, Homozygote, Humans, Huntington Disease, Male, Mesoderm, Mice, Inbred C57BL, Molecular Sequence Data, Nerve Tissue Proteins, Nuclear Proteins, Phenotype, Stem Cells, Gene Targeting, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.